Risk factors and impacts of child growth faltering in low- and middle-income countries

- 3 Andrew Mertens, 1* Jade Benjamin-Chung, 2 John M Colford Jr, 1 Jeremy Coyle 1, Mark J van der Laan, 1
- 4 Alan E Hubbard,¹ Sonali Rosete,¹ Ivana Malenica,¹ Nima Hejazi,¹ Oleg Sofrygin,¹ Wilson Cai,¹ Haodong Li,¹
- 5 Anna Nguyen, Nolan N Pokpongkiat, Stephanie Djajadi, Anmol Seth, Esther Jung, Esther O Chung,
- 6 Wendy Jilek, Vishak Subramoney, Ryan Hafen, Jonas Häggström, Thea Norman, Kenneth H Brown,
- 7 Parul Christian,⁸ Benjamin F. Arnold,^{9,10*} and members of the *ki* Child Growth Consortium**
- 9 ¹ Division of Epidemiology & Biostatistics, University of California, Berkeley, 2121 Berkeley Way Rm 5302
- 10 Berkeley, CA 94720-7360
- 11 ² Department of Epidemiology & Population Health, Stanford University, Stanford University, 259
- 12 Campus Drive, HRP Redwood Building T152A, Stanford, CA 94305
- 13 ³ DVPL Tech

1

2

8

- 14 ⁴ Hafen Consulting, LLC, West Richland WA, 99353
- 15 ⁵Cytel Inc, 1050 Winter St Suite 2700 Waltham, MA 02451, USA
- 16 ⁶ Quantitative Sciences, Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109
- 17 Department of Nutrition, University of California, Davis, 3135 Meyer Hall, Davis, CA 95616-5270
- 18 *Center for Human Nutrition, Department of International Health, Johns Hopkins Bloomberg School of
- 19 Public Health, Baltimore, MD 21205
- 9 Francis I. Proctor Foundation, University of California, San Francisco, 95 Kirkham St, San Francisco, CA
 94143
- Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, San Francisco, CA 94143
- * Corresponding authors are Andrew Mertens (amertens@berkeley.edu) and Benjamin F. Arnold (ben.arnold@ucsf.edu).
- 27 **Members of the *ki* Child Growth Consortium
- 28 1. Souheila Abbeddou, Food Safety and Nutrition Unit, Department of Public Health and Primary Care, Ghent University, Belgium
- 30 2. Linda S. Adair, University of North Carolina at Chapel Hill
- 31 3. Tahmeed Ahmed, International Centre for Diarrhoeal Disease Research, Bangladesh
- 32 4. Asad Ali, Aga Khan University
- 33 5. Hasmot Ali, JiVitA Project, Bangladesh, Johns Hopkins
- 34 6. Per Ashorn, Center for Child Health Research, Tampere University and Tampere University
- 35 Hospital, Finland
- 36 7. Rajiv Bahl, World Health Organization
- 37 8. Mauricio L. Barreto, Center of Data and Knowledge Integration for Health, Fundação Oswaldo
- 38 Cruz, Salvador, Brazil.
- 39 9. Elodie Becquey, International Food Policy Research Institute
- 40 10. France Begin, UNICEF
- 41 11. Pascal Obong Bessong, HIV/AIDS & Global Health Research Programme, University of Venda
- 42 12. Maharaj Kishan Bhan, Indian Institute of Technology, New Delhi, India
- 43 13. Zulfigar A. Bhutta, Institute for Global Health & Development & Center of Excellence in Women
- 44 and Child Health, The Aga Khan University South-Central Asia, East Africa & United Kingdom
- 45 14. Nita Bhandari, Centre for Health Research and Development, Society for Applied Studies, New
- 46 Delhi, India
- 47 15. Santosh K. Bhargava, Senior Consultant Pediatrics, Sunder Lal Jain Hospital, Ashok Vihar

- 48 16. Robert E. Black, Johns Hopkins University
- 49 17. Ladaporn Bodhidatta, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
- 50 18. Delia Carba, USC Office of Population Studies Foundation, Inc., University of San Carlos, Cebu,
- 51 Philippines
- 52 19. William Checkley, Johns Hopkins University
- 53 20. Parul Christian, Bill and Melinda Gates Foundation, Johns Hopkins Bloomberg School of Public
- 54 Health
- 55 21. Jean E. Crabtree, Leeds Institute for Medical Research, St. James's University Hospital, University
- 56 of Leeds
- 57 22. Kathryn G. Dewey, Institute for Global Nutrition, Department of Nutrition, University of
- 58 California
- 59 23. Christopher P. Duggan, Center for Nutrition, Boston Children's Hospital
- 60 24. Caroline H.D. Fall, Emeritus Professor of International Paediatric Epidemiology, MRC Lifecourse
- 61 Epidemiology Centre, University of Southampton, UK
- 62 25. Abu Syed Golam Faruque, International Centre for Diarrhoeal Disease Research, Bangladesh
- 63 26. Wafaie W. Fawzi, Department of Global Health and Population, Harvard TH Chan School of
- 64 Public Health
- 65 27. José Quirino da Silva Filho, Federal University of Ceará
- Robert H. Gilman, Johns Hopkins University Bloomberg School of Public Health
- 67 29. Richard Guerrant, University of Virginia.edu
- 68 30. Rashidul Haque, International Centre for Diarrhoeal Disease Research, Bangladesh
- 69 31. S. M. Tafsir Hasan, International Centre for Diarrhoeal Disease Research, Bangladesh
- 70 32. Sonja Y. Hess, Dept of Nutrition and Institute for Global Nutrition, University of California Davis
- 71 33. Eric R. Houpt, University of Virginia.edu
- 72 34. Jean H. Humphrey, Johns Hopkins Bloomberg School of Public Health
- 73 35. Najeeha Talat Igbal, Department of Pediatrics and Child Health, Aga Khan University
- 74 36. Elizabeth Yakes Jimenez, Departments of Pediatrics and Internal Medicine, University of New
- 75 Mexico Health Sciences Center
- 76 37. Jacob John, Christian Medical College, Vellore, Tamil Nadu, India
- 77 38. Sushil Matthew John, Professor, Low Cost Effective Care Unit, Christian Medical College, Vellore
- 78 TN 632004 India
- 79 39. Gagandeep Kang, Translational Health Science and Technology Institute, Faridabad, Haryana,
- 80 India
- 81 40. Margaret Kosek, University of Virginia
- 82 41. Michael S. Kramer, McGill University and McGill University Health Centre
- 83 42. Alain Labrique, Center of Human Nutrition, Department of International Health, Johns
- 84 Hopkins Bloomberg School of Public Health
- 85 43. Nanette R. Lee, USC-Office of Population Studies Foundation Inc., University of San Carlos, Cebu,
- 86 Philippines
- 87 44. Aldo Ângelo Moreira Lima, Federal University of Ceará
- 45. Tjale Cloupas Mahopo, Department of Nutrition, School of Health Sciences, University of Venda
- 89 46. Kenneth Maleta, Department of Public Health, School of Public Health and Family Medicine,
- 90 College of Medicine
- 91 47. Dharma S. Manandhar, Mother and Infant Research Activities
- 92 48. Karim P. Manji, Department of Pediatrics and Child Health, Muhimbili University School of
- 93 Health and Allied Sciences, Dar es Salaam, Tanzania
- 94 49. Reynaldo Martorell, Rollins School of Public Health, Emory University

- 95 50. Sarmila Mazumder, Centre for Health Research and Development, Society for Applied Studies,
- 96 New Delhi, India
- 97 51. Estomih Mduma, Haydom Lutheran Hospital, Haydom, Tanzania
- 98 52. Venkata Raghava Mohan, Professor, Community Medicine, Christian Medical College, Vellore TN
- 99 632004 India
- 100 53. Sophie E. Moore, Department of Women and Children's Health, Kings College London, London,
- 101 UK & MRC Unit The Gambia at London School of Hygiene and Tropical Medicine
- 102 54. Robert Ntozini, Zvitambo Institute for Maternal and Child Health Research
- 103 55. Mzwakhe Emanuel Nyathi, Department of Animal Sciences, School of Agriculture, University of
- 104 Venda
- 105 56. Maribel Paredes Olortegui, AB PRISMA
- 106 57. Césaire T. Ouédraogo, Institute for Global Nutrition, Department of Nutrition, University of
- 107 California, Davis, CA, USA
- 108 58. William A. Petri, University of Virginia
- 109 59. Prasanna Samuel Premkumar, Christian Medical College, Vellore, Tamil Nadu, India
- 110 60. Andrew M. Prentice, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine,
- 111 Banjul, The Gambia
- 112 61. Najeeb Rahman, Aga Khan University
- 113 62. Manuel Ramirez-Zea, INCAP Research Center for the Prevention of Chronic Diseases, Institute of
- 114 Nutrition of Central America and Panama, Guatemala City, Guatemala
- Harshpal Singh Sachdev, Senior Consultant Pediatrics and Clinical Epidemiology, Sitaram Bhartia
- 116 Institute of Science and Research, B-16 Qutab Institutional Area, New Delhi, India
- 117 64. Kamran Sadiq, Aga Khan University
- 118 65. Rajiv Sarkar, Christian Medical College, Vellore, Tamil Nadu, India
- 119 66. Monira Sarmin, International Centre for Diarrhoeal Disease Research, Bangladesh
- 120 67. Naomi M. Saville, Institute for Global Health, University College London
- 121 68. Saijuddin Shaikh, JiVitA Project, Bangladesh, Johns Hopkins
- 122 69. Bhim P. Shrestha, Health Research and Development Forum, Kathmandu, Nepal
- 123 70. Sanjaya Kumar Shrestha, MD, Walter Reed/AFRIMS Research Unit, Kathmandu, Nepal Centre for
- 124 International Health, University of Bergen
- 125 71. Alberto Melo Soares, Federal University of Ceará
- 126 72. Bakary Sonko, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul,
- 127 The Gambia
- 128 73. Aryeh D. Stein, Hubert Department of Global Health, Rollins School of Public Health, Emory
- 129 University

- 130 74. Erling Svensen, Haukeland University Hospital
- 131 75. Sana Syed, Department of Pediatrics, Division of Gastroenterology, Hepatology & Nutrition
- 132 University of Virginia School of Medicine, and Aga Khan University
- 133 76. Fayaz Umrani, Aga Khan University
- 134 77. Honorine D. Ward, Tufts Medical Center, Tufts University School of Medicine
- 135 78. Keith P. West Jr., Center for Human Nutrition, Department of International Health, Johns
- 136 Hopkins Bloomberg School of Public Health
- 137 79. Lee Shu Fune Wu, Center for Human Nutrition, Department of International Health, Johns
- 138 Hopkins Bloomberg School of Public Health
- 139 80. Seungmi Yang, McGill University
- 140 81. Pablo Penataro Yori, University of Virginia

Abstract limit ~200 words; current count 218

Main text limit 2000-3000 words; current count 3168

Summary

Growth faltering (low length-for-age or weight-for length) in the first 1000 days — from conception to two years of age — influences both short and long-term health and survival. Evidence for interventions to prevent growth faltering such as nutritional supplementation during pregnancy and the postnatal period has increasingly accumulated, but programmatic action has been insufficient to eliminate the high burden of stunting and wasting in low- and middle-income countries. In addition, there is need to better understand age-windows and population subgroups in which to focus future preventive efforts. Here, we show using a population intervention effects analysis of 33 longitudinal cohorts (83,671 children) and 30 separate exposures that improving maternal anthropometry and child condition at birth, in particular child length-at-birth, accounted for population increases by age 24 months in length-for-age Z of 0.04 to 0.40 and weight-for-length Z by 0.02 to 0.15. Boys had consistently higher risk of all forms of growth faltering than girls, and early growth faltering predisposed children to subsequent and persistent growth faltering. Children with multiple growth deficits had higher mortality rates from birth to two years than those without deficits (hazard ratios 1.9 to 8.7). The importance of prenatal causes, and severe consequences for children who experienced early growth faltering, support a focus on pre-conception and pregnancy as key opportunities for new preventive interventions.

Introduction

Child growth faltering in the form of stunting, a marker of chronic malnutrition, and wasting, a marker of acute malnutrition, is common among young children in low-resource settings, and may contribute to child mortality and adult morbidity. Worldwide, 22% of children under age 5 years are stunted and 7% are wasted, with most of the burden occurring in low- and middle-income counties (LMIC). Current estimates attribute >250,000 deaths annually to stunting and >1 million deaths annually to wasting. Stunted or wasted children also experience worse cognitive development and adult economic outcomes.

Despite widespread recognition of the importance of growth faltering to global public health, preventive interventions in LMICs have had limited success.⁸ A range of nutritional interventions targeting various life stages of the fetal and childhood periods, including nutrition education, food and micronutrient supplementation during pregnancy, promotion of exclusive breastfeeding for 6 months and continued breastfeeding for 2 years, and food and micronutrient supplementation during complementary feeding, have all had a beneficial effect on child growth.^{9–11} However, postnatal

breastfeeding interventions and nutritional interventions delivered to children who have begun complementary feeding have only had small effects on population-level stunting and wasting burdens, and implementation remains a substantial challenge. 9,11,12 Additionally, water, sanitation, and hygiene (WASH) interventions, which aim to reduce childhood infections that may heighten the risk of wasting and stunting, have had no effect on child growth in several recent large randomized control trials. 13–15

Modest effects of interventions to prevent stunting and wasting may reflect an incomplete understanding of the optimal way and time to intervene. This knowledge gap has spurred renewed interest in recent decades to combine rich data sources with advances in statistical methodology to more deeply understand the key causes of growth faltering. Understanding the relationship between the causes and timing of growth faltering is also crucial because children who falter early could be at higher risk for more severe growth faltering later. In companion articles, we report that the highest rates of incident stunting and wasting occur by age 3 months. 18,19

Pooled longitudinal analyses

Here, we report a pooled analysis of 33 longitudinal cohorts in 15 low- and middle-income countries in South Asia, Sub-Saharan Africa, Latin America, and Eastern Europe, initiated between 1969 and 2014. Our objective was to estimate relationships between child, parental, and household characteristics and measures of child anthropometry, including length-for-age Z-scores (LAZ), weight-for-length Z-scores (WLZ), weight-for-age Z-scores (WAZ), stunting, wasting, underweight, and length and weight velocities from birth to age 24 months. Details on the estimation of growth faltering outcomes are included in companion articles. We also estimated associations between early growth faltering and more severe growth faltering or mortality by age 24 months.

Cohorts were assembled as part of the Bill & Melinda Gates Foundation's Knowledge Integration (ki) initiative, which included studies of growth and development in the first 1000 days, beginning at conception.²⁰ We selected longitudinal cohorts from the database that met five inclusion criteria: 1) conducted in low- or middle-income countries; 2) enrolled children between birth and age 24 months and measured their length and weight repeatedly over time; 3) did not restrict enrollment to acutely ill children; 4) enrolled children with a median year of birth after 1990; and 5) collected anthropometric status measurements at least every 3 months (Extended Data Fig 1). Inclusion criteria ensured we could rigorously evaluate the timing and onset of growth faltering among children who were broadly representative of populations in low- and middle-income countries. Thirty-three cohorts from 15 countries met inclusion criteria, and 83,671 children and 592,030 total measurements were included in this analysis (Fig 1). Child mortality was rare and not reported in many of the ki datasets, so we relaxed inclusion criteria for studies used in the mortality analysis to include studies that measured children at least twice a year. Four additional cohorts met this inclusion criterion, and 14,317 children and 70,733 additional measurements were included in mortality analyses (97,988 total children, 662,763 total observations, Extended Data Table 1). Cohorts were distributed throughout South Asia, Africa, and Latin America, with a single European cohort from Belarus.

Population intervention effects on growth faltering

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

In a series of analyses, we estimated population intervention effects, the estimated change in population mean Z-score if all individuals in the population had their exposure shifted from observed levels to the lowest-risk reference level.²¹ The PIE is a policy-relevant parameter; it estimates the improvement in outcome that could be achievable through intervention for modifiable exposures, as it is a function of the degree of difference between the unexposed and the exposed in a children's anthropometry Z-scores, as well as the observed distribution of exposure in the population. We selected exposures that were measured in multiple cohorts, could be harmonized across cohorts for pooled analyses, and had been identified as important predictors of stunting or wasting in prior literature (Fig 1, Extended Data Table 2). Different cohorts measured different sets of exposures, but all estimates were adjusted for all other measured exposures that we assumed were not on the causal pathway between the exposure of interest and the outcome (Fig 1). Different cohorts measured different sets of exposures, but all estimates were adjusted for all other measured exposures that we assumed were not on the causal pathway between the exposure of interest and the outcome (Fig 1). For example, the association between maternal height and stunting was not adjusted for a child's birthweight because low maternal height could increase stunting risk through lower child birthweight, an assumption we tested in a mediation analysis.²² Parameters were estimated using targeted maximum likelihood estimation, a doubly-robust, semiparametric method that allows for valid inference while adjusting for potential confounders using ensemble machine learning (details in Methods). 17,23 We estimated cohortspecific parameters, adjusting for measured covariates within each cohort, and then pooled estimates across cohorts using random effects models (Extended data Fig 1).²⁴ We chose the reference as the level of lowest risk across cohorts. We also estimated the effects of optimal dynamic interventions, where each child's individual low-risk level of exposure was estimated from potential confounders (details in Methods). Timing of exposures varied, from parental and household characteristics present before birth, to fetal or at-birth exposures, and postnatal exposures including breastfeeding and diarrheal disease. We estimated only associations for growth faltering occurring after exposure measurements to ensure time-ordering of exposures and outcomes.

Population level improvements in maternal height and birth length and weight would be expected to improve child LAZ and WLZ at age 24 months substantially, owing to both the high prevalence of suboptimal anthropometry in the populations and their strong association with attained growth at 24 months (Fig 2a, 2b). Beyond anthropometry, key predictors of higher Z-scores included markers of better household socioeconomic status (e.g., number of rooms in the home, parental education, clean cooking fuel use, household wealth index) and Cesarean-section, which may reflect healthcare access or larger fetal size. Unique to WLZ, the population level impact of season was large, with higher WLZ in drier periods, consistent with seasonal differences shown in the companion article.¹⁹ The pooled, cross-validated R² for models that included the top 10 determinants for each Z-score, plus child sex, was 0.26 for LAZ (N= 19 cohorts, 23,922 children) and 0.06 for WLZ (N=29 cohorts, 22,588 children). Exclusive or predominant breastfeeding before 6 months of age was associated with higher WLZ but not LAZ at 6 months of age and was not a major predictor of Z-scores at 24 months, as expected (Extended Data Figs 2,3,4).²⁵

The findings underscore the importance of prenatal exposures for child growth outcomes, and at the population-level growth faltering may be difficult to shift without broad improvements in

standard of living.^{7,26} Maternal anthropometric status can influence child Z-scores by affecting fetal growth and birth size.^{27,28} Maternal height and BMI could directly affect postnatal growth through breastmilk quality, or could reflect family poverty, genetics, undernutrition, or food insecurity, or family lifestyle and diet.^{29,30} In a secondary analysis, we estimated the associations between parental anthropometry and child Z-scores controlling for birth characteristics, and found the associations were only partially mediated by birth size, order, C-section, hospital delivery, and gestational age at birth. (Extended data Fig 5), with adjusted Z-score differences attenuating by a median of 31.5%

The strongest predictors of stunting and wasting estimated through population attributable fractions closely matched those identified for child LAZ and WLZ at 24 months (Extended Data Fig 6), suggesting that information embedded in continuous and binary measures of child growth provide similar inference with respect to identifying public-health relevant causes. Potential improvements through population interventions were relatively modest. For example, if all children were born to higher BMI mothers (≥ 20) compared to the observed distribution of maternal BMI, one of the largest predictors of wasting, we estimate it would reduce the incidence of wasting by age 24 months by 8.2% (95% CI: 4.4, 12.0; Extended Data Fig 6a). Patterns in associations across growth outcomes were broadly consistent, except for preterm birth, which had a stronger association with stunting outcomes than wasting outcomes, and rainy season, which was strongly associated with wasting but not stunting (Extended Data Fig 2). Direction of associations did not vary across regions, but magnitude did, notably with male sex less strongly associated with low LAZ in South Asia (Extended Data Figs 7,8).

Age-varying effects on growth faltering

We estimated trajectories of mean LAZ and WLZ stratified by maternal height and BMI. We found that maternal height strongly influenced at-birth LAZ, but that LAZ progressed along similar trajectories through age 24 months regardless of maternal height (Fig 3a), with similar though slightly less pronounced differences when stratified by maternal BMI (Fig 3b). By contrast, children born to taller mothers had similar WLZ at birth and WLZ trajectories until age 3-4 months, when they diverged substantially (Fig 3a); WLZ trajectory differences were even more pronounced when stratified by maternal BMI (Fig 3b). The findings illustrate how maternal status strongly influences where child growth trajectories start, but that growth trajectories evolve in parallel, seeming to respond similarly to postnatal insults independent of their starting point.

Children who were stunted by age 3 months exhibited a different longitudinal growth trajectory from those who were stunted later. We hypothesized that causes of growth faltering could differ by age of growth faltering onset. For key exposures identified in the population attributable effect analyses, we conducted analyses stratified by age of onset and in many cases found age-varying effects (Fig 3c). For example, most measures of socioeconomic status were associated with incident wasting or stunting only after age 6 months, and higher birth order lowered growth faltering risk under age 6 months, but increased risk thereafter. The specific mechanism for effect modification of birth order on growth faltering by age is unknown, but primiparous mothers may be younger, have lower pre-pregnancy weight, have lower weight gain during pregnancy, or have less experience breastfeeding — a key source of nutrition during the first 6 months — while children with older siblings could have lower quality and quantity of complementary foods compared with firstborn children in food insecure households.

Stronger relationships between key socio-demographic characteristics and wasting and stunting as children age likely reflects the accumulation of insults that result from household conditions, particularly as complementary feeding is initiated, and children begin exploring their environment and potentially face higher levels of food insecurity especially in homes with multiple children.³¹ When viewed across multiple definitions of growth faltering, most factors had stronger associations with severe stunting, severe wasting, or persistent wasting (> 50% of measurements < -2 WLZ), rarer but more serious outcomes, than with incidence of any wasting or stunting (Fig 3d). Additionally, the characteristics strongly associated with lower probability of recovering from a wasting episode in 90 days (birth size, small maternal stature, lower maternal education, later birth order, and male sex) were also characteristics associated with higher risk of wasting prevalence and cumulative incidence (Extended data fig 2).

Consequences of early growth faltering

We documented high incidence rates of wasting and stunting from birth to age 6 months in companion papers. ^{18,19} Based on previous studies, we hypothesized that early wasting could contribute to subsequent linear growth restriction, and early growth faltering could be consequential for persistent growth faltering and mortality during the first 24 months of life. ^{32–34} Among cohorts with monthly measurements, we examined age-stratified linear growth velocity by quartiles of WLZ at previous ages. We found a consistent exposure-response relationship between higher mean WLZ and faster linear growth velocity in the following 3 months (Fig 4a), with a corresponding inverse relationship between WLZ and incident stunting at older ages (Extended data Fig 9). Persistent wasting from birth to 6 months (defined as > 50% of measurements wasted) was the wasting measure most strongly associated with incident stunting at older ages (Fig 4b).

We next examined the relationship between measures of growth faltering in the first 6 months and serious growth-related outcomes: persistent wasting from 6-24 months and concurrent wasting and stunting at 18 months of age, both of which put children at high risk of mortality. ^{1,32} Concurrent wasting and stunting was measured at 18 months because stunting prevalence peaked at 18 months and the largest number of children were measured at 18 months across cohorts. ¹⁸ All measures of early growth faltering were significantly associated with later, more serious growth faltering, with measures of ponderal growth faltering amongst the strongest predictors (Fig 4c).

Finally, we estimated hazard ratios (HR) of all-cause mortality by 2 years of age associated with measures of growth faltering within eight cohorts that reported ages of death, which included 1,689 child deaths by age 24 months (2.4% of children in the eight cohorts). Included cohorts were highly monitored, and mortality rates were lower than in the general population in most cohorts (Extended Data Table 3). Additionally, data included only deaths that occurred after anthropometry measurements, so many neonatal deaths may have been excluded, and without data on cause-specific mortality, some deaths may have occurred from causes unrelated to growth faltering. Despite these caveats, growth faltering increased the hazard of death before 24 months for all measures except stunting alone, with strongest associations observed for severe wasting, stunting, and underweight (HR=8.7, 95% CI: 4.7, 16.4) and severe underweight alone (HR=4.2, 95% CI: 2.0, 8.6) (Fig 4d).

Discussion

This synthesis of LMIC cohorts during the first 1000 days of life has provided new insights into the principal drivers and near-term consequences of growth faltering. Our use of a novel, semi-parametric method to adjust for potential confounding provided a harmonized approach to estimate population intervention effects that spanned child-, parent-, and household-level exposures with unprecedented breadth (30 exposures) and scale (662,763 anthropometric measurements from 33 cohorts). Our focus on effects of shifting population-level exposures on continuous measures of growth faltering reflect a growing appreciation that growth faltering is a continuous process. Our results show children in LMICs stand to benefit from interventions to support optimal growth in the first 1000 days. Combining information from high-resolution, longitudinal cohorts enabled us to study critically important outcomes not possible in smaller studies or in cross-sectional data, such as persistent wasting and mortality, as well as examine risk-factors by age.

We found that maternal, prenatal, and at-birth characteristics were the strongest predictors of growth faltering across regions in LMICs. Many predictors, like child sex or season, are not modifiable but could guide interventions that mitigate their effects, such as seasonally targeted supplementation or enhanced monitoring among boys. Strong associations between maternal anthropometry and early growth faltering highlights the role of intergenerational transfer of growth faltering between mothers and their children.²⁹ Shifting several key population exposures (maternal height or BMI, education, birth length) to their observed low-risk level would improve LAZ and WLZ in target populations and could be expected to improve Z-scores by 0.06 to 0.4 Z in the study populations and prevent 8% to 32% of incident stunting and wasting (Fig 2, Extended Data Fig 6). Maternal anthropometric status strongly influenced birth size, but the parallel drop in postnatal Z-scores among children born to different maternal phenotypes was much larger than differences at birth, indicating that growth trajectories were not fully "programmed" at birth (Fig 3a-b).

Previous studies have implicated prenatal exposures as key determinants of child growth faltering,³⁶ and our finding of a limited impact of exclusive or predominant breastfeeding through 6 month (+0.01 LAZ) is congruent with a meta-analysis of breastfeeding promotion,²⁵ but our findings of limited impact of reducing diarrhea through 24 months (+0.05 LAZ) contrast with some observational studies.^{37,38} We found that growth faltering before age 6 months puts children at far higher risk of persistent wasting and concurrent wasting and stunting at older ages (Fig 4c), which predispose children to longer-term morbidity and mortality. Our results agree with the limited success of numerous postnatal preventive interventions in recent decades,^{10,11,39-41} as well as evidence that improvements in maternal education, nutrition, parity, and maternal and newborn health care are primary contributors in countries that have had the most success in reducing stunting,⁴² reinforcing the importance of interventions during the window from conception to one year, when fetal and infant growth velocity is high.⁴³ A recent study examining metabolism across the life span identified infancy as one of the highest periods of energy needs related to growth or development with energy expenditure (adjusted for fat-free mass) by 1 year being about 50% above adult values.⁴³

The analyses had caveats. In some cases, detailed exposure measurements like longitudinal breastfeeding or diarrhea history were coarsened to simpler measures to harmonize definitions across

cohorts, potentially attenuating their association with growth faltering. Other key exposures such as dietary diversity, nutrient consumption, micronutrient status, maternal and child morbidity indicators, pathogen-specific infections, and sub-clinical inflammation and intestinal dysfunction were measured in only a few cohorts, so were not included. The absence of these exposures in the analysis, some of which have been found to be important within individual contributed cohorts, that our results emphasize exposures that were more commonly collected, but likely exclude some additional causes of growth faltering.

Our results suggest that targeting the next generation of interventions toward reproductive age and pregnant women could be a promising path forward to prevent growth faltering amongst their children. The recent Women's First trial found prenatal nutrition supplements improved children's birth size, though there was no impact of giving supplements starting pre-conception compared to starting late in the first trimester. Emerging evidence suggests that interventions beyond nutrition, such as those that address maternal infection and inflammation, may further contribute to decreasing in utero growth faltering. Personal infection and inflammation, may further contribute to decreasing in utero growth faltering. Nevertheless, a stronger focus on prenatal interventions should not distract from renewed efforts for postnatal prevention. Wasting and stunting incidence was highest before age 6 months, but mean LAZ decreased until age 18 months, the concurrence of wasting and stunting peaked at age 18 months, and large, seasonally driven declines in WLZ were observed across all ages. Targeting postnatal interventions such as small-quantity lipid-based nutrient supplements shown to reduce stunting, wasting and anemia and perhaps by season or by population subgroups defined by socioeconomic or household or individual characteristics identified herein should help focus preventive interventions to reduce the substantial, persistent burden of postnatal growth faltering.

References

- 1. McDonald, C. M. *et al.* The effect of multiple anthropometric deficits on child mortality: meta-analysis of individual data in 10 prospective studies from developing countries. *Am. J. Clin. Nutr.* **97**, 896–901 (2013).
- 2. Forouzanfar, M. H. *et al.* Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet* **388**, 1659–1724 (2016).
- 3. WHO | Joint child malnutrition estimates Levels and trends (2019 edition). WHO http://www.who.int/nutgrowthdb/estimates2018/en/.
- 4. Sudfeld, C. R. *et al.* Malnutrition and Its Determinants Are Associated with Suboptimal Cognitive, Communication, and Motor Development in Tanzanian Children. *J. Nutr.* **145**, 2705–2714 (2015).
- 5. Black, R. E. *et al.* Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* **382**, 427–451 (2013).
- 421 6. Grantham-McGregor, S. *et al.* Developmental potential in the first 5 years for children in developing countries. *The Lancet* **369**, 60–70 (2007).
- 423 7. McGovern, M. E., Krishna, A., Aguayo, V. M. & Subramanian, S. V. A review of the evidence linking child stunting to economic outcomes. *Int. J. Epidemiol.* **46**, 1171–1191 (2017).
- 8. Bhutta, Z. A. *et al.* What works? Interventions for maternal and child undernutrition and survival. *Lancet* **371**, 417–440 (2008).
- Panjwani, A. & Heidkamp, R. Complementary Feeding Interventions Have a Small but Significant Impact on Linear and Ponderal Growth of Children in Low- and Middle-Income Countries: A
 Systematic Review and Meta-Analysis. *J. Nutr.* 147, 2169S-2178S (2017).

- 430 10. Bhutta, Z. A. *et al.* Evidence-based interventions for improvement of maternal and child nutrition: what can be done and at what cost? *The Lancet* **382**, 452–477 (2013).
- 432 11. Dewey, K. G. *et al.* Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. *medRxiv* 2021.02.05.21251105 (2021) doi:10.1101/2021.02.05.21251105.
- 435 12. Stewart, C. P., Iannotti, L., Dewey, K. G., Michaelsen, K. F. & Onyango, A. W. Contextualising complementary feeding in a broader framework for stunting prevention. *Matern. Child. Nutr.* **9**, 27–45 (2013).
- 438 13. Null, C. *et al.* Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial. *Lancet Glob. Health* 440 **6**, e316–e329 (2018).
- 14. Luby, S. P. *et al.* Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial. *Lancet Glob. Health* **6**, e302–e315 (2018).
- Humphrey, J. H. *et al.* Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. *Lancet Glob. Health* **7**, e132–e147 (2019).
- 16. Young, H. & Marshak, A. A discussion paper on the scope of the problem, its drivers, and strategies for moving forward for policy, practice, and research. 55.
- 449 17. Coyle, J. et al. (submitted). Targeting Learning: Robust Statistics for Reproducible Research. (2020).
- 450 18. Benjamin-Chung, J. et. al. (submitted). Early childhood linear growth faltering in low-and middle-income countries. (2020).
- 452 19. Mertens, A. *et al.* (submitted). Child wasting and concurrent stunting in low- and middle-income countries. (2020).
- 20. Peppard, T. *et al.* (submitted). Combined longitudinal growth cohorts from infants born in South Asia, Sub-Saharan Africa and Latin America. (2020).
- 456 21. Westreich, D. From Patients to Policy: Population Intervention Effects in Epidemiology. *Epidemiol.* 457 *Camb. Mass* **28**, 525–528 (2017).
- 458 22. Varela-Silva, M. I., Azcorra, H., Dickinson, F., Bogin, B. & Frisancho, A. R. Influence of maternal stature, pregnancy age, and infant birth weight on growth during childhood in Yucatan, Mexico: A test of the intergenerational effects hypothesis. *Am. J. Hum. Biol.* **21**, 657–663 (2009).
- 461 23. Gruber, S. & Laan, M. van der. Targeted Maximum Likelihood Estimation: A Gentle Introduction. *UC Berkeley Div. Biostat. Work. Pap. Ser.* (2009).
- 463 24. Raudenbush, S. W. Analyzing Effect Sizes: Random-Effects Models. in *The Handbook of Research Synthesis and Meta-Analysis* 295–315 (Russell Sage Foundation, 2009).
- 465 25. Giugliani, E. R. J., Horta, B. L., Mola, C. L. de, Lisboa, B. O. & Victora, C. G. Effect of breastfeeding promotion interventions on child growth: a systematic review and meta-analysis. *Acta Paediatr.* **104**, 20–29 (2015).
- 468 26. Haddad, L., Alderman, H., Appleton, S., Song, L. & Yohannes, Y. Reducing Child Malnutrition: How Far Does Income Growth Take Us? *World Bank Econ. Rev.* 17, 107–131 (2003).
- 470 27. Young, M. F. *et al.* Role of maternal preconception nutrition on offspring growth and risk of stunting across the first 1000 days in Vietnam: A prospective cohort study. *PloS One* **13**, e0203201 (2018).
- 472 28. Addo, O. Y. et al. Maternal Height and Child Growth Patterns. J. Pediatr. 163, 549-554.e1 (2013).
- 473 29. Martorell, R. & Zongrone, A. Intergenerational Influences on Child Growth and Undernutrition. *Paediatr. Perinat. Epidemiol.* **26**, 302–314 (2012).
- 30. Bzikowska-Jura, A. *et al.* Maternal Nutrition and Body Composition During Breastfeeding: Association with Human Milk Composition. *Nutrients* **10**, (2018).
- 31. Garg, A. & Morduch, J. Sibling rivalry and the gender gap: Evidence from child health outcomes in Ghana. *J. Popul. Econ.* **11**, 471–493 (1998).
- 479 32. Myatt, M. et al. Children who are both wasted and stunted are also underweight and have a high risk

- of death: a descriptive epidemiology of multiple anthropometric deficits using data from 51 countries. *Arch. Public Health* **76**, (2018).
- 482 33. Richard, S. A. *et al.* Wasting Is Associated with Stunting in Early Childhood123. *J. Nutr.* **142**, 1291–1296 (2012).
- 34. Stobaugh, H. C. *et al.* Children with Poor Linear Growth Are at Risk for Repeated Relapse to Wasting after Recovery from Moderate Acute Malnutrition. *J. Nutr.* **148**, 974–979 (2018).
- 486 35. Perumal, N., Bassani, D. G. & Roth, D. E. Use and Misuse of Stunting as a Measure of Child Health. *J. Nutr.* **148**, 311–315 (2018).
- 36. Christian, P. *et al.* Risk of childhood undernutrition related to small-for-gestational age and preterm birth in low- and middle-income countries. *Int J Epidemiol* **42**, 1340–1355 (2013).
- 490 37. Schlaudecker, E. P., Steinhoff, M. C. & Moore, S. R. Interactions of diarrhea, pneumonia, and malnutrition in childhood: recent evidence from developing countries. *Curr. Opin. Infect. Dis.* **24**, 496–492 502 (2011).
- 38. Akombi, B. J. *et al.* Stunting, Wasting and Underweight in Sub-Saharan Africa: A Systematic Review. *Int. J. Environ. Res. Public. Health* **14**, (2017).
- 39. Bhutta, Z. A. *et al.* What works? Interventions for maternal and child undernutrition and survival. *The Lancet* **371**, 417–440 (2008).
- 497 40. Piwoz, E., Sundberg, S. & Rooke, J. Promoting Healthy Growth: What Are the Priorities for Research and Action?12. *Adv. Nutr.* **3**, 234–241 (2012).
- 41. Kristjansson, E. *et al.* Food supplementation for improving the physical and psychosocial health of socio-economically disadvantaged children aged three months to five years. *Cochrane Database Syst. Rev.* CD009924 (2015) doi:10.1002/14651858.CD009924.pub2.
- 502 42. Bhutta, Z. A. *et al.* How countries can reduce child stunting at scale: lessons from exemplar countries. *Am. J. Clin. Nutr.* **112**, 894S-904S (2020).
- 504 43. Pontzer, H. *et al.* Daily energy expenditure through the human life course. *Science* **373**, 808–812 (2021).
- 506 44. Black, R. E. *et al.* Maternal and child undernutrition: global and regional exposures and health consequences. *Lancet* **371**, 243–260 (2008).

509

510

- 45. Kosek, M. *et al.* Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. *Am. J. Trop. Med. Hyg.* **88**, 390–396 (2013).
- 511 46. Investigators, M.-E. N. Relationship between growth and illness, enteropathogens and dietary intakes in the first 2 years of life: findings from the MAL-ED birth cohort study. *BMJ Glob. Health* **2**, (2017).
- 513 47. WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience. (World Health Organization, 2016).
- 48. Ota, E., Hori, H., Mori, R., Tobe-Gai, R. & Farrar, D. Antenatal dietary education and supplementation to increase energy and protein intake. *Cochrane Database Syst. Rev.* (2015)
 doi:10.1002/14651858.CD000032.pub3.
- 518 49. Hambidge, K. M. *et al.* A multicountry randomized controlled trial of comprehensive maternal nutrition supplementation initiated before conception: the Women First trial. *Am. J. Clin. Nutr.* **109**, 457–469 (2019).
- 521 50. Hallamaa, L. *et al.* The impact of maternal antenatal treatment with two doses of azithromycin and monthly sulphadoxine-pyrimethamine on child weight, mid-upper arm circumference and head circumference: A randomized controlled trial. *PLOS ONE* **14**, e0216536 (2019).
- 524 51. Hallamaa, L. *et al.* Child Health Outcomes After Presumptive Infection Treatment in Pregnant Women: A Randomized Trial. *Pediatrics* **141**, (2018).
- 52. Hendrixson, D. T. *et al.* A novel intervention combining supplementary food and infection control measures to improve birth outcomes in undernourished pregnant women in Sierra Leone: A randomized, controlled clinical effectiveness trial. *PLOS Med.* **18**, e1003618 (2021).




Figure 1 | Cohort sample sizes and exposures measured. (a) Total number of children with a measured exposure, sorted from left to right by number of cohorts measuring the exposure. (b) Presence of 30 exposure variables in the *ki* data by within each included cohort. Cohorts are sorted by geographic region and sample size. (c) Number child anthropometry observations contributed by each cohort.




Figure 2 | Population intervention effects of child, parental, and household exposures on length-for-age z-scores and weight-for-length z-scores at age 24 months.

- (a) Population intervention effects on child length-for-age z-scores (LAZ) at age 24 months.
- **(b)** Population intervention effects on child weight-for-length z-scores (WLZ) at age 24 months.

Exposures were rank ordered in both panels by effects on LAZ. Each exposure label includes the reference level used to estimate population intervention effects, shifting exposures for all children from their observed exposure to the reference level. Cohort-specific estimates were adjusted for all measured confounders using ensemble machine learning and TMLE, and then pooled using random effects (Methods). Columns for each exposure summarize the number of children that contributed to each analysis and the percentage of children for whom exposure was shifted to the reference level, and the estimated population intervention effect (PIE) and 95% confidence interval.




Figure 3 | Effect of key exposures on the trajectories, timing, and severity of child growth faltering

- (a) Child length-for-age Z-score (LAZ) and weight-for-length Z-score (WLZ) trajectories, stratified by categories of maternal height (N=413,921 measurements, 65,061 children, 20 studies).
- (**b**) Child LAZ and WLZ, stratified by categories of maternal BMI (N=373,382 measurements, 61,933 children, 17 studies).

564

565

566 567

568

569

570

571

(c) Associations between key exposures and wasting cumulative incidence, stratified by the age of the child during wasting incidence. Gray points indicate cohort-specific

estimates.

(d) Associations between key exposures and growth faltering of different severities. Contrasts are between the highest and lowest risk exposure category of each exposure, which are printed in each panel title. Gray points indicate cohort-specific estimates.






Figure 4 | Early life growth faltering increases risk of more severe growth faltering and mortality.

- (a) Adjusted differences in linear growth velocity (in centimeters) across 3-month age bands, by quartile of weight-for-length z-score (WLZ) in the preceding three months. The reference group is children in the first quartile of WLZ in the previous age period. The panel with black points on the far right shows the pooled estimates, unstratified by child age. Velocity was calculated from the closest measurements within 14 days of the start and end of the age period.
- (b) Relative risk of stunting onset after age 6 months between children who experienced measures of early wasting compared to children who did not experience the measure of early wasting. Gray points indicate cohort-specific estimates.
- (c) Association between cumulative incidences before age 6 months of combinations of growth faltering and persistent wasting from ages 6-24 months (33 cohorts, 6,046 cases, and 68,645 children) and concurrent wasting and stunting at 18 months. (31 cohorts, 1,447 cases, and 22,565 children). Combined measures of growth faltering occurred in the same measurement, though children may not have experienced the combined measurement during other measurements before 6 months.
- (d) Hazard ratios between non-overlapping measures of growth faltering and mortality before 24 months (8 cohorts, 1,689 deaths with ages of death, and 63,812 children).
- Gray points indicate cohort-specific estimates in figures a-d.



Extended Data Figure 1 | Example forest plot of cohort-specific and pooled parameter estimates

Cohort-specific estimates of the cumulative incidence ratio of stunting are plotted on each row, comparing the risk of any stunting from birth to 24 months among boys compared to a reference level of girls. Below the solid horizontal line are region-specific pooled measures of association, pooled using random-effects models. Below the dashed line are overall pooled measures of association, comparing pooling using random or fixed effects models. The primary results reported throughout the manuscript are overall (not region stratified) estimates pooled using random effects models.



Extended Data Figure 2 | Heatmap of significance and direction across exposureoutcome combinations.

617

618


619 620

621

The heatmap shows the significance and direction of estimates through the cell colors, separated across primary outcomes by child age. Red and orange cells are exposures where the outcome is estimated have an increased probability of

occurring compared to the reference level (harmful exposures except for recovery outcomes), while blue and green cells are exposures associated with a decreased probability of the outcome (protective exposures except for recovery outcomes). The outcomes are labeled at the top of the columns, with each set of three columns the set of three ages analyzed for that outcome. Each row is a level of an exposure variable, with reference levels excluded. Rows are sorted top to bottom by increasing average p-value. Grey cells denote comparisons that were not estimated or could not be estimated because of data sparsity in the exposure-outcome combination. All point estimates and confidence intervals for exposure-outcome pairs with P-values plotted in this figure are viewable online at (https://child-growth.github.io/causes).


Population intervention effect - LAZ, stratified by age



Extended Data Figure 3 | Age-stratified population intervention effects in length-for-age Z-scores.


Exposures, rank ordered by population intervention effect on child LAZ, stratified by the age of the child at the time of anthropometry measurement. The population intervention effect is the expected difference in mean Z-score if all children had the reference level of the exposure rather than the observed exposure distribution. For all plots, reference levels are printed in the exposure label. Estimates were adjusted for all other measured exposures not on the causal pathway.

Population intervention effect - WLZ, stratified by age




Extended Data Figure 4 | Age-stratified population intervention effects in weightfor-length Z-scores.

Exposures, rank ordered by population intervention effects on child WLZ,, stratified by the age of the child at the time of anthropometry measurement. The population intervention effect is the expected difference in population mean Z-score if all children had the reference level of the exposure rather than the observed distribution. For all plots, reference levels are printed next to the name of the exposure. Estimates are adjusted for all other measured exposures not on the causal pathway.



Extended Data Figure 5 | Mediation of parental anthropometry effects by birth size on child Z-scores at 24 months.

Mediating effect of adjusting for birth anthropometry and at-birth characteristics on the estimated Z-score differences between levels of parental anthropometry. Primary estimates were adjusted for all other measured exposures not on the causal pathway, while the mediation analysis estimates were additionally adjusted for birth weight, birth length, gestational age at birth, birth order, vaginal birth vs. C-section, and home vs. hospital delivery. Only estimates from cohorts measuring at least 4 of the 6 at-birth characteristics were used to estimate the pooled Z-score differences (n = 7 cohorts, 17,130 observations). Mediation estimates were slightly attenuated toward the null, and only in the case of maternal height and child LAZ were they statistically different from the primary analysis. These results imply that the causal pathway between parental anthropometry and growth faltering operates through its effect on birth size, but most of the effect is through other pathways.




Extended Data Figure 6 | Rank-ordered associations between child, parental, and household characteristics and population attributable fractions of stunting and wasting.

- (a) Exposures, rank ordered by population intervention effect on the cumulative incidence of child stunting between birth and 24 months.
- **(b)** Exposures, rank ordered by population intervention effect on the cumulative incidence of child wasting between birth and 24 months.

The population attributable fraction is the estimated proportion of the observed outcome in the whole population attributable to the exposure. For at-birth exposures, at-birth stunting and wasting is excluded, and for postnatal exposures including breastfeeding practice and diarrheal disease, the cumulative incidence of stunting


and wasting from 6-24 months is used. For all plots, reference levels are printed next to the name of the exposure. Estimates are adjusted for all other measured exposures not on the causal pathway.

Population intervention effect - LAZ, stratified by region




Extended Data Figure 7 | Regionally-stratified population attributable differences in length-for-age Z-scores.

Exposures, rank ordered by population intervention effect on child LAZ at 24 months, stratified by region. The population intervention effect is the expected difference in population mean Z-score if all children had the reference level of the exposure rather than the observed distribution. For all plots, reference levels are printed next to the name of the exposure. Estimates were adjusted for all other measured exposures not on the causal pathway.




Extended Data Figure 8 | Regionally-stratified population attributable differences in weight-for-length Z-scores.

Exposures, rank ordered by population attributable difference on child WLZ at 24 months, stratified by region. The population attributable difference is the expected difference in population mean Z-score if all children had the reference level of the exposure rather than the observed distribution. For all plots, reference levels are printed next to the name of the exposure. Estimates were adjusted for all other measured exposures not on the causal pathway




Extended Data Figure 9 | Comparing fixed-reference and optimal intervention estimates of the population intervention effect.

Pooled population intervention effects on child LAZ and WHZ at 24 months, with the X-axis showing attributable differences using a fixed, and the Y-axis showing the optimal intervention attributable difference, where the level the exposure is shifted to can vary by child. Points are labeled with the specific risk factor. Estimates farther from the diagonal line have larger differences between the static and optimal intervention estimates. The optimal intervention attributable differences, which are not estimated with an a-priori specified low-risk reference level, were generally close to the static attributable differences, indicating that the chosen reference levels were the lowest risk strata in most or all children.



Extended Data Figure 10 | Difference between adjusted and unadjusted Z-score effects by number of selected adjustment variables.

Points mark the difference in estimates unadjusted and adjusted estimates of the difference in average Z-scores between exposed and unexposed children across 33 cohorts, 30 exposures and length-for-age and weight-for-length Z-score outcomes included in the analysis. Different cohorts measured different sets of exposures, and a different number of adjustment covariates were chosen for each cohort-specific estimate based on outcome sparsity, so cohort-specific estimates adjust for different covariates and numbers of covariates. The plot shows no systematic bias between unadjusted and adjusted estimates based on number of covariates chosen. The blue line shows the average difference between adjusted estimates from unadjusted estimates, fitted using a cubic spline.



Extended Data Figure 12 | Assessing sensitivity of estimates to unmeasured confounding using E-values

744745

746

An E-value is the minimum strength of association in terms of relative risk that an unmeasured confounder would need to have with both the exposure and the outcome to

explain away an estimated exposure—outcome association.¹ Orange points mark the E-values for the pooled estimates of relative risk for each exposure. Grey points are cohort-specific E-values for each exposure-outcome relationship. Non-significant pooled estimates have points plotted at 1.0. Orange points are median E-values among statistically significant estimates for each exposure. As an example, an unmeasured confounder would on average need to almost double the risk of both the exposure and the outcome to explain away observed significant associations for the birth length exposure.

Extended data table 1

				Childre			
				n	Anthropometry	Total	
		Study		Enrolle	measurement ages	measure	Primary
Region, Study ID	Country	Years	Design	d*	(months)	ments*	References
South Asia	1 - 2				,		
Journ Asia			Prospec				Igbal et al 2018
		2013-	tive				Nature Scientific
Biomarkers for EE	Pakistan	2015	cohort	380	Birth, 1, 2,, 18	8918	Reports ²
			Prospec		, , , ,		Ali et al 2016
		2011 -	tive				Journal of Medical
Resp. Pathogens	Pakistan	2014	cohort	284	Birth, 1, 2,, 17	3177	Virology ³
		2012 -	Prospec				
Growth Monitoring		Ongoi	tive				
Study	Nepal	ng	cohort	698	Birth, 1, 2,, 24	13487	Not yet published
			Prospec				Shrestha et al
		2010 -	tive				2014 Clin Infect
MAL-ED	Nepal	2014	cohort	240	Birth, 1, 2,, 24	5936	Dis ⁴
			Prospec				
CMC Birth Cohort,		2002 -	tive	070	B: 11 0 5 4 4 5 04	0404	Gladstone et al.
Vellore	India	2006	cohort	373	Birth, 0.5, 1, 1.5,, 24	9131	2011 NEJM ⁵
		2040	Prospec				laba at al 2044
MAL ED	lua ali a	2010 -	tive	254	Di-4- 4 0 04	5047	John et al 2014
MAL-ED	India	2012	cohort	251	Birth, 1, 2,, 24	5947	Clin Infect Dis ⁶
		2008 -	Prospec tive				Kattula et al. 2014
Vellore Crypto Study	India	2008 -	cohort	410	Birth, 1, 2,, 24	9825	BMJ Open ⁷
velible Crypto Study	IIIula	2011	Prospec	410	Dittil, 1, 2,, 24	9023	ымы Ореп
	Banglad	1993 -	tive				Pathela et al 2007
CMIN	esh	1996	Cohort	280	Birth 3 6 24	5399	Acta Paediatrica ⁸
TDC	India	2008-	Quasi-	160	Birth, 3, 6,, 24 Birth, 1, 2,, 24	3723	Sarkar et al. 2013
1.23	IIIGIG	2011	experim	100	Bitai, 1, 2,, 21	0.20	BMC Public Health
			ental				
			Prospec				
	Banglad	2010 -	tive				Ahmed et al 2014
MAL-ED	esh	2014	cohort	265	Birth, 1, 2,, 24	5816	Clin Infect Dis ⁹
					Birth, 6, 10, 12, 14. 17,		Kirkpatrick et al
	Banglad	2011 -	Individu		18, 24, 39, 40, 52, 53		2015 Am J Trop
PROVIDE RCT	esh	2014	al RCT	700	(weeks)	12165	Med Hyg ¹⁰
		1995 -	Individu				Bhandari et al
Food Suppl RCT	India	1996	al RCT	418	Baseline, 6, 9, 12	2242	2001 J Nutri ¹¹
Optimal Infant	l	1999 -	Cluster	,	B		Bhandari et al
Feeding	India	2001	RCT	1535	Birth, 3, 6,, 18	9539	2004 J Nutri ¹²
			Prospec	_			
	Banglad	2008 -	tive				Korpe et al. 2016
NIH Birth Cohort	esh	2009	Cohort	629	Birth, 3, 6,, 12	6216	PLOS NTD ¹³
	Banglad	2012 -	Cluster				Christian et al 2015
JiVitA-4 Trial	esh	2014	RCT	5444	6, 9, 12, 14, 18	36167	IJE ¹⁴
17 // A O T : :	Banglad	2008 -	Cluster	0=0.15	B: # 4 0 0 40 04	400505	West et al JAMA
JiVitA-3 Trial	esh	2012	RCT	27342	Birth, 1, 3, 6, 12, 24	109535	2014 ¹⁵

NIH Cryptosporidium	Banglad	2014 -	Prospec tive				Steiner et al 2018
Study	esh	2017	cohort	758	Birth, 3, 6,, 24	9774	Clin Infect Dis ¹⁶
•							
A.C.:							
Africa			Prospec				
	Tanzani	2009 -	tive				Mduma et al 2014
MAL-ED	a	2014	cohort	262	Birth, 1, 2,, 24	5857	Clin Infect Dis ¹⁷
	Tanzani	2007 -	Individu	-	, , , ,		Locks et al Am J
Tanzania Child 2	а	2011	al RCT	2400	1, 2,, 20	32198	Clin Nutr 2016 ¹⁸
			Prospec				
	South	2009 -	tive				Bessong et al 20°
MAL-ED	Africa	2014	cohort	314	Birth, 1, 2,, 24	6478	Clin Infect Dis ¹⁹
MRC Keneba		1987 -					Schoenbuchner e
	Gambia	1997	Cohort	2931	Birth, 1, 2,, 24	40952	al. 2019, AJCN ²⁰
7) ((TANADO T : 1	Zimbab	1997 -	Individu	44404	B: # 0 1 0 0 0 10	70054	Malaba et al 2005
ZVITAMBO Trial	we	2001	al RCT	14104	Birth, 6 wks, 3, 6, 9, 12	73651	Am J Clin Nutr ²¹
Lummura Child		2011 -	las alicai alca				Mangani et al. 2015, Mat Child
Lungwena Child Nutrition RCT	Molowi	2011 -	Individu al RCT	940	Dieth 1 6 wk 6 12 19	4346	Nutr ²²
NUMBER OF REAL	Malawi Burkina	2014	Cluster	840	Birth, 1-6 wk, 6, 12 18	4340	Hess et al 2015
iLiNS-Zinc Study	Faso	2010 -	RCT	3266	9, 12, 15, 18	10552	Plos One ²³
CMIN GB94	Guinea	1994 -	Prospec	870	Enrollment and every 3	6459	Valentiner-Branth
OMIN ODS4	Bissau	1997	tive	010	months after	0400	2001 Am J Clin
	Bioodd	1007	Cohort		months and		Nutr
Latin America	· L	· L					
Latin America			Prospec				
		2009 -	tive				Yori et al 2014 Cl
MAL-ED	Peru	2014	cohort	303	Birth, 1, 2,, 24	6442	Infect Dis ²⁴
100 KE EB	1 0.4	2011	Prospec	000	5, 1, 2,, 21	0112	Jaganath et al
		2007 -	tive				2014
CONTENT	Peru	2011	cohort	215	Birth, 1, 2,, 24	8339	Helicobacter ²⁵
	Guatem	1997 -	Individu				Begin et al. 2008.
Bovine Serum RCT	ala	1998	al RCT	315	Baseline, 1, 2,,8	2551	EJČN ²⁶
			Prospec				
		2010 -	tive				Lima et al 2014
MAL-ED	Brazil	2014	cohort	233	Birth, 1, 2,, 24	5092	Clin Infect Dis ²⁷
CMIN Brazil89	Brazil	1989-	Prospec	119	Birth, 1, 2,, 24	889	Moore et al. 2001
		2000	tive				Int J Epidemiol.
CMIN Peru95	Dom	1005	Cohort	224	Birth, 1, 2,, 24	2070	Charlelay at al
Civilin Peru95	Peru	1995 - 1998	Prospec tive	224	Birth, 1, 2,, 24	3979	Checkley et al. 2003 Am J
		1990	Cohort				Epidemiol.
CMIN Peru89	Peru	1989 -	Prospec	210	Birth, 1, 2,, 24	2742	Checkley et al.
Civilia i ciuos	l eiu	1991	tive	210	Dirtii, 1, 2,, 24	2142	1998 Am J
		1001	Cohort				Epidemiol.
Europe	1	1000	Chroter				Kromer et -1 000
PROBIT Study	Belarus	1996 - 1997	Cluster RCT	16898	1 2 2 6 0 42	124509	Kramer et al 200° JAMA ²⁸
i Nobii Suuy	Delaius	1881	NOT	10090	1, 2, 3, 6, 9, 12	124009	JAIVIA
Mortality analysis only	,		_				
Burkina Faso Zinc	Burkina	2010-	Cluster				Becquey et al 20
trial	Faso	2011	RCT	7167	6, 10, 14, 17, 22	15155	J Nutr ²⁹
		1005					WHO CHD Vitam
	1	1995-	Cluster	0000	4 0 0 0 46	00==5	A Group 1998
Vitamin A Trial	India	1996	RCT	3983	1, 3, 6, 9, 12	32570	Lancet ³⁰
ILING DOOF	Malari	2009-	Individu	4000	6 0 10 10	40004	Maleta et al. 201
iLiNS-DOSE	Malawi	2011	al RCT	1932	6, 9, 12, 18	13801	J Nutr ²²
ILINO-DUSE							
iLiNS-DOSE	Malawi	2011- 2015	Individu al RCT	1235	1, 6, 12, 18	9207	Ashorn et al 2015 J. Nutr ²²

Extended data table 2

All exposures included in the analysis, as well as the categories the exposures were classified into across all cohorts, categorization rules, and the total number of children and percent of children in each category. We selected the exposures of interest based on variables present in multiple cohorts that met our inclusion criteria, were found to be important determinants of stunting and wasting in prior literature, and could be harmonized across cohorts for pooled analyses.

Exposure variable	N children under 24 months with both measured exposure and length	Exposure levels [N (%)] First listed level is reference	Categorization rules
Sex	78751	Female: 38444 (48.8%) Male: 40307 (51.2%)	
Gestational age at birth	45269	Full or late term: 23313 (51.5%) Preterm: 6328 (14%) Early term: 15628 (34.5%)	<260 days is preterm, [260-274) days is early term, >= 274 is full term
Birthweight (kg)	46099	1: 17294 (37.5%) 2: 14107 (30.6%) 3+: 14698 (31.9%)	
Birth length (cm)	46099	1: 17294 (37.5%) 2: 14107 (30.6%) 3+: 14698 (31.9%)	
Birth order	46099	1: 17294 (37.5%) 2: 14107 (30.6%) 3+: 14698 (31.9%)	
Delivery location	8487	0: 2793 (32.9%) 1: 5694 (67.1%)	
Delivery method	63259	0: 5108 (8.1%) 1: 58151 (91.9%)	
Maternal weight	59256	>=45 kg: 40338 (68.1%) <45 kg: 18918 (31.9%)	Cutoff chosen because a 45kg heavy, 19 year old woman has a WAZ of -2
Maternal height	60742	>=150 cm: 44831 (73.8%) <150 cm: 15911 (26.2%)	Cutoff chosen because a 150cm tall, 19 year old woman has a HAZ of -2
Maternal body mass index (BMI)	57627	>=20 BMI: 34952 (60.7%) < 20 BMI: 22675 (39.3%)	Calculated from maternal height and weight. Excludes mothers whose only weight measurement was taken during pregnancy. A 45 kg, 150 cm woman (the cutoffs for height and weight) has a BMI of 20.
Mother's age	70548	[20-30): 41707 (59.1%) <20: 17826 (25.3%) >=30: 11015 (15.6%)	
Maternal education	69971	High: 23013 (32.9%) Low: 23702 (33.9%) Medium: 23256 (33.2%)	Classified by splitting distribution of numbers of years of educations into thirds within each cohort, or grouping ordered categories of educational attainment into three levels.
Paternal height	15772	>=162 cm: 15079 (95.6%) <162 cm: 693 (4.4%)	Cutoff chosen because a 162cm tall, 19 year old man has a HAZ of -2
Paternal age	18976	>=35: 2289 (12.1%) <30: 13002 (68.5%)	

		[30-35): 3685 (19.4%)	
Paternal education	65728	High: 12684 (19.3%) Low: 23089 (35.1%) Medium: 29955 (45.6%)	Classified by splitting distribution of numbers of years of educations into thirds within each cohort, or grouping ordered categories of educational attainment into three levels.
Caregiver marital status	38222	0: 36393 (95.2%) 1: 1829 (4.8%)	
Asset based household wealth index	36754	WealthQ4: 9618 (26.2%) WealthQ3: 9165 (24.9%) WealthQ2: 9012 (24.5%) WealthQ1: 8959 (24.4%)	First principal component of a principal components analysis of all recorded assets owned by the household (examples: cell phone, bicycle, car).
Household food security	24461	Food Secure: 12534 (51.2%) Mildly Food Insecure: 7921 (32.4%) Food Insecure: 4006 (16.4%)	Combination of three food security scales: 1. The Household Hunger Scale (HHS) ³¹ 2. Food Access Survey Tool (FAST) ³² 3. USAID Household Food Insecurity Access Scale (HFIAS), with middle 2 categories classified as mildly food insecure. ³³ And one survey question from the NIH Bangladesh birth cohort and NIH Bangladesh Cryptosporidium cohort: "In terms of household food availability, how do you classify your household?" 1. Deficit in whole year 2. Sometimes deficit 3. Neither deficit nor surplus 4. Surplus Where the middle two categories were classified as mildly food insecure.
Improved floor	35354	1: 4693 (13.3%) 0: 30661 (86.7%)	,
Improved sanitation	35086	1: 24119 (68.7%) 0: 10967 (31.3%)	WHO Joint Monitoring program definition
Improved water source	35284	1: 33777 (95.7%) 0: 1507 (4.3%)	WHO Joint Monitoring program definition
Clean cooking fuel usage	1401	1: 407 (29.1%) 0: 994 (70.9%)	
Number of children <5 in the household	31610	1: 18963 (60%) 2+: 12647 (40%)	
Number of individuals in the household	1805	3 or less: 363 (20.1%) 4-5: 745 (41.3%) 6-7: 452 (25%) 8+: 245 (13.6%)	
Number of rooms in household	35929	4+: 2492 (6.9%) 1: 20210 (56.2%) 2: 9484 (26.4%)	

		3: 3743 (10.4%)	
Rain season	9769	Opposite max rain: 2469 (25.3%) Pre max rain: 2248 (23.0%) Max rain: 2718 (27.8%) Post max rain: 2334 (23.9%)	Rainfall data was extracted from Terraclimate, a dataset that combines readings from WorldClim data, CRU Ts4.0, and the Japanese 55-year Reanalysis Project. The reach study region, we averaged all readings within a 50 km radius from the study coordinates. If GPS locations were not in the data for a cohort, we used the approximate location of the cohort based on the published descriptions of the cohort. The three-month period opposite the three months of maximum rainfall was used as the reference level (e.g., if June-August was the period of maximum rainfall, the reference level is child mean WLZ during January-March). Due to the time-varying nature of this exposure, N's are reported for children with length measures at 24 months and measures of rain season.
Breastfed hour after birth	49168	1: 11609 (23.6%) 0: 37559 (76.4%)	
Exclusive or predominant breastfeeding in the first 6 months of life	26173	1: 18285 (69.9%) 0: 7888 (30.1%)	Exclusive breastfeeding: mother reported only feeding child breastmilk on all dietary surveys Predominant breastfeeding: mother reported only feeding child breastmilk, other liquids, or medicines on all dietary surveys
Cumulative percent of days with diarrhea under 6 months	3735	[0%, 2%]: 2245 (60.1%) >2%: 1490 (39.9%)	Percent days defined as proportion of disease surveillance days a child had diarrhea during. Diarrhea defined by 3 or more loose stools, or bloody stool, in a 24 hour period. Only included studies with at least 100 disease surveillance measurements during age range.
Cumulative percent of days with diarrhea under 24 months	12639	[0%, 2%]: 6133 (48.5%) >2%: 6506 (51.5%)	Percent days defined as proportion of disease surveillance days a child had diarrhea during. Diarrhea defined by 3 or more loose stools, or bloody stool, in a 24 hour period. Only included studies with at least 100 disease surveillance measurements during age range.

Extended data table 3

769

770

771

772

773774775

Under 1-year country-specific mortality rate is from UNICEF (https://data.unicef.org/country), and is higher than the cohort-specific under 2-year mortality rate for all cohorts used in the mortality analysis.

Study	Country	Number of deaths under 2	Under 2 mortality rate in cohort (%)	Infant (Under 1) mortality rate in cohort (%)	Infant (Under 1) mortality country rate (UNICEF
Burkina Faso Zn	Burkina Faso	39	0.54	0.42	5.4
iLiNS-DOSE	Malawi	53	2.74	1.92	3.1
iLiNS- DYAD-M	Malawi	54	4.37	3.48	3.1
JiVitA-3	Bangladesh	934	3.41	2.85	2.6
JiVitA-4	Bangladesh	49	0.9	0.39	2.6
Keneba	The Gambia	65	2.22	1.52	3.6
VITAMIN-A	India	108	2.70	2.7	2.8
ZVITAMBO	Zimbabwe	1113	7.89	6.57	3.8

Supplementary References

- VanderWeele, T. J. & Ding, P. Sensitivity Analysis in Observational Research: Introducing the E Value. *Ann. Intern. Med.* 167, 268 (2017).
- Iqbal, N. T. *et al.* Promising Biomarkers of Environmental Enteric Dysfunction: A Prospective Cohort
 study in Pakistani Children. *Sci. Rep.* 8, 2966 (2018).
- 3. Ali, A. *et al.* Respiratory viruses associated with severe pneumonia in children under 2 years old in a rural community in Pakistan. *J. Med. Virol.* **88**, 1882–1890 (2016).
- 782 4. Shrestha, P. S. *et al.* Bhaktapur, Nepal: The MAL-ED Birth Cohort Study in Nepal. *Clin. Infect. Dis.*783 59, S300–S303 (2014).
- 784 5. Gladstone, B. P. *et al.* Protective Effect of Natural Rotavirus Infection in an Indian Birth Cohort. *N.* 785 *Engl. J. Med.* 365, 337–346 (2011).
- 786 6. John, S. M. *et al.* Establishment of the MAL-ED Birth Cohort Study Site in Vellore, Southern India.
 787 *Clin. Infect. Dis.* **59**, S295–S299 (2014).

- 788 7. Kattula, D. et al. The first 1000 days of life: prenatal and postnatal risk factors for morbidity and
- growth in a birth cohort in southern India. BMJ Open 4, e005404 (2014).
- 790 8. Pathela, P. et al. Diarrheal illness in a cohort of children 0-2 years of age in rural Bangladesh: I.
- Incidence and risk factors: Risk factors for diarrhea in Bangladeshi children. Acta Paediatr. 95, 430–
- 792 437 (2007).
- 793 9. Ahmed, T. et al. The MAL-ED Cohort Study in Mirpur, Bangladesh. Clin. Infect. Dis. 59, S280–S286
- 794 (2014).
- 795 10. Kirkpatrick, B. D. et al. The "Performance of Rotavirus and Oral Polio Vaccines in Developing
- Countries" (PROVIDE) Study: Description of Methods of an Interventional Study Designed to Explore
- 797 Complex Biologic Problems. *Am. J. Trop. Med. Hyg.* **92**, 744–751 (2015).
- 11. Bhandari, N. *et al.* Food Supplementation with Encouragement to Feed It to Infants from 4 to 12
- 799 Months of Age Has a Small Impact on Weight Gain. *J. Nutr.* **131**, 1946–1951 (2001).
- 800 12. Bhandari, N. et al. An Educational Intervention to Promote Appropriate Complementary Feeding
- Practices and Physical Growth in Infants and Young Children in Rural Haryana, India. J. Nutr. 134,
- 802 2342–2348 (2004).
- 13. Korpe, P. S. et al. Natural History of Cryptosporidiosis in a Longitudinal Study of Slum-Dwelling
- Bangladeshi Children: Association with Severe Malnutrition. *PLoS Negl. Trop. Dis.* **10**, (2016).
- 14. Christian, P. et al. Effect of fortified complementary food supplementation on child growth in rural
- Bangladesh: a cluster-randomized trial. *Int. J. Epidemiol.* **44**, 1862–1876 (2015).
- 807 15. West, K. P. et al. Effect of Maternal Multiple Micronutrient vs Iron–Folic Acid Supplementation on
- 808 Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial.
- *JAMA* **312**, 2649–2658 (2014).
- 810 16. Steiner, K. L. et al. Species of Cryptosporidia Causing Subclinical Infection Associated With Growth
- Faltering in Rural and Urban Bangladesh: A Birth Cohort Study. Clin. Infect. Dis. Off. Publ. Infect. Dis.
- 812 Soc. Am. 67, 1347–1355 (2018).
- 813 17. Mduma, E. R. et al. The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition
- and the Consequences for Child Health and Development Study (MAL-ED): Description of the

- 815 Tanzanian Site. Clin. Infect. Dis. **59**, S325–S330 (2014).
- 18. Locks, L. M. *et al.* Effect of zinc and multivitamin supplementation on the growth of Tanzanian
- children aged 6–84 wk: a randomized, placebo-controlled, double-blind trial12. Am. J. Clin. Nutr. 103,
- 818 910–918 (2016).
- 819 19. Bessong, P. O., Nyathi, E., Mahopo, T. C. & Netshandama, V. Development of the Dzimauli
- Community in Vhembe District, Limpopo Province of South Africa, for the MAL-ED Cohort Study.
- 821 Clin. Infect. Dis. **59**, S317–S324 (2014).
- 822 20. Schoenbuchner, S. M. et al. The relationship between wasting and stunting: a retrospective cohort
- analysis of longitudinal data in Gambian children from 1976 to 2016. Am. J. Clin. Nutr.
- 824 doi:10.1093/ajcn/nqy326.
- 825 21. Malaba, L. C. et al. Effect of postpartum maternal or neonatal vitamin A supplementation on infant
- mortality among infants born to HIV-negative mothers in Zimbabwe. *Am. J. Clin. Nutr.* **81**, 454–460
- 827 (2005).
- 828 22. Mangani, C. et al. Effect of complementary feeding with lipid-based nutrient supplements and corn-
- 829 soy blend on the incidence of stunting and linear growth among 6- to 18-month-old infants and
- 830 children in rural Malawi. *Matern. Child. Nutr.* **11**, 132–143 (2015).
- 831 23. Hess, S. Y. et al. Small-Quantity Lipid-Based Nutrient Supplements, Regardless of Their Zinc
- 832 Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting in Young Burkinabe
- 833 Children: A Cluster-Randomized Trial. *PLOS ONE* **10**, e0122242 (2015).
- 24. Yori, P. P. et al. Santa Clara de Nanay: The MAL-ED Cohort in Peru. Clin. Infect. Dis. 59, S310–S316
- 835 (2014).
- 836 25. Jaganath, D. et al. First Detected Helicobacter pylori Infection in Infancy Modifies the Association
- 837 Between Diarrheal Disease and Childhood Growth in Peru. *Helicobacter* **19**, 272–279 (2014).
- 838 26. Bégin, F., Santizo, M.-C., Peerson, J. M., Torún, B. & Brown, K. H. Effects of bovine serum
- concentrate, with or without supplemental micronutrients, on the growth, morbidity, and micronutrient
- status of young children in a low-income, peri-urban Guatemalan community. Eur. J. Clin. Nutr. 62,
- **841** 39–50 (2008).

842 27. Lima, A. A. M. et al. Geography, Population, Demography, Socioeconomic, Anthropometry, and 843 Environmental Status in the MAL-ED Cohort and Case-Control Study Sites in Fortaleza, Ceará, 844 Brazil. Clin. Infect. Dis. 59, S287-S294 (2014). 845 28. Kramer, M. S. et al. Promotion of Breastfeeding Intervention Trial (PROBIT): A Randomized Trial in 846 the Republic of Belarus. JAMA 285, 413-420 (2001). 847 29. Becquey, E. et al. Comparison of Preventive and Therapeutic Zinc Supplementation in Young 848 Children in Burkina Faso: A Cluster-Randomized, Community-Based Trial. J. Nutr. 146, 2058–2066 849 (2016).850 30. Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation 851 in early infancy. The Lancet 352, 1257–1263 (1998). 852 31. Ballard, T., Coates, J., Swindale, A. & Deitchler, M. Household Hunger Scale: Indicator Definition and 853 Measurement Guide. 23. 854 32. Coates, J. Measuring Food Insecurity: Going Beyond Indicators of Income and Anthropometry. 106 855 (1825).856 33. Coates, J., Swindale, A. & Bilinsky, P. Household Food Insecurity Access Scale (HFIAS) for 857 Measurement of Food Access: Indicator Guide: Version 3: (576842013-001). (2007) 858 doi:10.1037/e576842013-001. 859 34. Abatzoglou, J. T., Dobrowski, S. Z., Parks, S. A. & Hegewisch, K. C. TerraClimate, a high-resolution 860 global dataset of monthly climate and climatic water balance from 1958–2015. Sci. Data 5, 170191 861 (2018).862 863 864 865 866 867 868 869

Materials and Methods

1. Study designs and inclusion criteria

We included all longitudinal observational studies and randomized trials available through the *ki* project on April 1, 2018 that met five inclusion criteria: 1) conducted in low- or middle-income countries; 2) enrolled children between birth and age 24 months and measured their length and weight repeatedly over time; 3) did not restrict enrollment to acutely ill children; 4) enrolled children with a median year of birth after 1990; 5) collected anthropometry measurements at least quarterly. We included all children under 24 months of age, assuming months were 30.4167 days, and we considered a child's first measure recorded by age 7 days as their anthropometry at birth. Four additional studies with high-quality mortality information that measured children at least every 6 months were included in the mortality analyses (The Burkina Faso Zinc trial, The Vitamin-A trial in India, and the iLiNS-DOSE and iLiNS-DYAD-M trials in Malawi).

2. Statistical analysis

Analyses were conducted in R version 4.0.5. All pooled, regional, and cohort-specific results, results for secondary outcomes, and sensitivity analyses are available online at (https://child-growth.github.io/causes).

3. Outcome definitions

We calculated length-for-age Z-scores (LAZ), weight-for-age Z-scores (WAZ), and weight-for-length Z-scores (WLZ) using WHO 2006 growth standards. We used the medians of triplicate measurements of heights and weights of children from pre-2006 cohorts to re-calculate Z-scores to the 2006 standard. We dropped 1,190 (0.2%) unrealistic measurements of LAZ (>+6 or <-6 Z), 1,330 (0.2%) measurements of WAZ (> 5 or <-6 Z), and 1,670 (0.3%) measurements of WLZ (>+5 or -5 Z), consistent with WHO recommendations. See Benjamin-Chung (2020) for more details on cohort inclusion and assessment of anthropometry measurement quality. We also calculated the difference in linear and ponderal growth velocities over three-month periods. We also calculated the difference in linear and ponderal growth velocities over three-month periods. We calculated the change in LAZ, WAZ, length in centimeters, and weight in kilograms within 3-month age intervals, including measurements within a two-week window around each age in months to account for variation in the age at each length measurement.

We defined stunting as LAZ < -2, severe stunting as LAZ < -3, underweight as WAZ < -2, severe underweight as WAZ < -3, wasting as WLZ < -2, severe wasting as WLZ < -3, concurrent stunting and wasting as LAZ < -2 and WLZ < -2. Children with $\geq 50\%$ of WLZ measurements < -2 and at least 4 measurements over a defined age range were classified as persistently wasted (e.g., birth to 24 months, median interval between measurements: 80 days, IQR: 62-93). Children were assumed to never recover from stunting episodes, but children were classified as recovered from wasting episodes (and at risk for a new episode of wasting) if their measured WLZ was ≥ -2 for at least 60 days (details in Mertens et. al (2020)). Stunting reversal was defined as children stunted under 3 months whose final two

measurements before 24 months were non-stunted. Child mortality was all-cause and was restricted to children who died after birth and before age 24 months. For child morbidity outcomes (Figure 4c), concurrent wasting and stunting prevalences at age 18 months were estimated using the anthropometry measurement taken closest to age 18 months, and within 17-19 months of age, while persistent wasting was estimated from child measurements between 6 and 24 months of age. We chose 18 months to calculate concurrent wasting and stunting because it maximized the number of child observations at later ages when concurrent wasting and stunting was most prevalent, and used ages 6-24 months to define persistent wasting to maximize the number of anthropometry measurements taken after the early growth faltering exposure measurements.⁴

4. Estimating relationships between child, parental, and household exposures and measures of growth faltering

4.1 Exposure definitions

We selected the exposures of interest based on variables present in multiple cohorts that met our inclusion criteria, were found to be important predictors of stunting and wasting in prior literature and could be harmonized across cohorts for pooled analyses. Extended Data Table 2 lists all exposures included in the analysis, as well as exposure categories used across cohorts, and the total number of children in each category. For parental education and asset-based household wealth, we categorized to levels relative to the distribution of educational attainment within each cohort. Continuous biological characteristics (gestational age, birth weight, birth height, parental weight, parental height, parental age) were classified based on a common distribution, pooling data across cohorts. Our rationale was that the meaning of socioeconomic variables is culturally context-dependent, whereas biological variables should have a more universal meaning.

4.2 Risk set definition

For exposures that occur or exist before birth, we considered the child at risk of incident outcomes at birth. Therefore, we classified children who were born stunted (or wasted) as incident episodes of stunting (or wasting) when estimating the relationship between household characteristics, paternal characteristics, and child characteristics like gestational age, sex, birth order, and birth location.

For postnatal exposures (e.g., breastfeeding practices, WASH characteristics, birth weight), we excluded episodes of stunting or wasting that occurred at birth. Children who were born wasted could enter the risk set for postnatal exposures if they recovered from wasting during the study period (see Mertens et al. 2020 for details).⁴ This restriction ensured that for postnatal exposures, the analysis only included postnatal, incident episodes. Children born or enrolled wasted were included in the risk set for the outcome of recovery from wasting within 90 days for all exposures (prenatal and postnatal).

4.3 Estimating differences in outcomes across categories of exposures

We estimated measures of association between exposures and growth faltering outcomes by comparing outcomes across categories of exposures in four ways:

<u>Mean difference</u> of the comparison levels of the exposure on LAZ, WLZ at birth, 6 months, and 24 months. The Z-scores used were the measures taken closest to the age of interest and within one month of the age of interest, except for Z-scores at birth which only included a child's first measure recorded by age 7 days. We also calculated mean differences in LAZ, WAZ, weight, and length velocities.

<u>Prevalence ratios (PR)</u> between comparison levels of the exposure, compared to the reference level at birth, 6 months, and 24 months. Prevalence was estimated using anthropometry measurements closest to the age of interest and within one month of the age of interest, except for prevalence at birth which only included measures taken on the day of birth.

<u>Cumulative incidence ratios (CIR)</u> between comparison levels of the exposure, compared to the reference level, for the incident onset of outcomes between birth and 24 months, 6-24 months, and birth-6 months.

Mean Z-scores by continuous age, stratified by levels of exposures, from birth to 24 months were fit within individual cohorts using cubic splines with the bandwidth chosen to minimize the median Akaike information criterion across cohorts.⁵ We estimated splines separately for each exposure category. We pooled spline curves across cohorts into a single prediction, offset by mean Z-scores at one year, using random effects models.⁶

4.4 Estimating population attributable parameters

We estimated three measures of the population-level effect of exposures on growth faltering outcomes:

<u>Population intervention impact</u> (PIE), a generalization of population attributable risk, was defined as the change in population mean Z-score if the entire population's exposure was set to an ideal reference level. For each exposure, we chose reference levels based on prior literature or as the category with the highest mean LAZ or WLZ across cohorts.

<u>Population attributable fraction</u> (PAF) was defined as the proportional reduction in cumulative incidence if the entire population's exposure was set to an ideal low risk reference level. We estimated the PAF for the prevalence of stunting and wasting at birth, 6, and 24 months and cumulative incidence of stunting and wasting from birth to 24 months, 6-24 months, and from birth to 6 months. For each exposure, we chose the reference level as the category with the lowest risk of stunting or wasting.

Optimal individualized intervention impact We employed a variable importance measure (VIM) methodology to estimate the impact of an optimal individualized intervention on an exposure.⁷ The optimal intervention on an exposure was determined through estimating individualized treatment regimes, which give an individual-specific rule for the lowest-risk level of exposure

based on individuals' measured covariates. The covariates used to estimate the low-risk level are the same as those used for the adjustment documented in section 6 below. The impact of the optimal individualized intervention is derived from the VIM, which is the predicted change in the population-mean outcome from the observed outcome if every child's exposure was shifted to the optimal level. This differs from the PIE and PAF parameters in that we did not specify the reference level; moreover, the reference level could vary across participants.

PIE and PAF parameters assume a causal relationship between exposure and outcome. For some exposures, we considered attributable effects to have a pragmatic interpretation — they represent a summary estimate of relative importance that combines the exposure's strength of association and its prevalence in the population. Comparisons between optimal intervention estimates and PIE estimates are shown in Extended Data Fig 9.

5. Estimation approach

Estimation of cohort-specific effects

For each exposure, we used the directed acyclic graph (DAG) framework to identify potential confounders from the broader set of exposures used in the analysis. We did not adjust for characteristics that were assumed to be intermediate on the causal path between any exposure and the outcome, because while controlling for mediators may help adjust for unmeasured confounders in some conditions, it can also lead to collider bias. Detailed lists of adjustment covariates used for each analysis are available online (https://child-growth.github.io/causes/dags.html). Confounders were not measured in every cohort, so there could be residual confounding in cohort-specific estimates.

For missing covariate observations, we imputed missing measurements as the median (continuous variables) or mode (categorical variables) among all children within each cohort, and analyses included an indicator variable for missingness in the adjustment set. When calculating the median for imputation, we used children as independent units rather than measurements so that children with more frequent measurements were not over-represented.

Unadjusted PRs and CIRs between the reference level of each exposure and comparison levels were estimated using logistic regressions. ¹² Unadjusted mean differences for continuous outcomes were estimated using linear regressions.

To flexibly adjust for potential confounders and reduce the risk of model misspecification, we estimated adjusted PRs, CIRs, and mean differences using targeted maximum likelihood estimation (TMLE), a two-stage estimation strategy that incorporates state-of-the-art machine learning algorithms (super learner) while still providing valid statistical inference. ^{13,14} The effects of covariate adjustment on estimates compared to unadjusted estimates is show bin in Extended Data Fig 10, and E-values, summary measures of the strength of unmeasured confounding needed to explain away observed significant associations, are plotted in Extended Data Fig 11. ¹⁵ The super learner is an ensemble machine learning method that uses cross-validation to select a weighted combination of predictions from a library of algorithms. ¹⁶ We included in the library simple means, generalized linear models, LASSO penalized regressions, ¹⁷ generalized additive models, ¹⁸ and gradient boosting machines. ¹⁹ The super learner was fit to maximize the 10-fold cross-validated area under the receiver operator curve (AUC) for

binomial outcomes, and minimize the 10-fold cross-validated mean-squared error (MSE) for continuous outcomes. That is, the super learner was fit using 9/10 of the data, while the AUC/MSE was calculated on the remaining 1/10 of the data. Each fold of the data was held out in turn and the cross-validated performance measure was calculated as the average of the performance measures across the ten folds. This approach is practically appealing and robust in finite samples, since this cross-validation procedure utilizes unseen sample data to measure the estimator's performance. Also, the super learner is asymptotically optimal in the sense that it is guaranteed to outperform the best possible algorithm included in the library as sample size grows. The initial estimator obtained via super learner is subsequently updated to yield an efficient double-robust semi-parametric substitution estimator of the parameter of interest. To estimate the R² of models including multiple exposures, we fit super learner models, without the targeted learning step, and within each cohort measuring the exposures. We then pooled cohort-specific R² estimates using fixed effects models.

We estimated influence curve-based, clustered standard errors to account for repeated measures in the analyses of recovery from wasting or progression to severe wasting. We assumed that the children were the independent units of analysis unless the original study had a clustered design, in which case the unit of independence in the original study were used as the unit of clustering. We used clusters as the unit of independence for the iLiNS-Zinc, Jivita-3, Jivita-4, Probit, and SAS Complementary Feeding trials. We estimated 95% confidence intervals for incidence using the normal approximation.

Mortality analyses estimated hazard ratios using Cox proportional hazards models with a child's age in days as the timescale, adjusting for potential confounders, with the growth faltering exposure status updated at each follow-up that preceded death or censoring by age 24 months. Growth faltering exposures included moderate (between –2 Z and –3 Z) wasting, stunting, and underweight, severe (below –3 Z) wasting, stunting, and underweight, and combinations of concurrent wasting, stunting, and underweight. Growth faltering categories were mutually exclusive within moderate or severe classifications, so children were classified as only wasted, only stunted, or only underweight, or some combination of these categories. We estimated the hazard ratio associated with different anthropometric measures of CGF in separate analyses, considering each as an exposure in turn with the reference group defined as children without the deficit. For children who did not die, we defined their censoring date as the administrative end of follow-up in their cohort, or age 24 months (730 days), whichever occurred first. Because mortality was a rare outcome, estimates are adjusted only for child sex and trial treatment arm. To avoid reverse causality, we did not include child growth measures occurring within 7 days of death. Extended Data Table 3 lists the cohorts used in the mortality analysis, the number of deaths in each cohort, and a comparison to country-level infant mortality rates.

Data sparsity

We did not estimate relative risks between a higher level of exposure and the reference group if there were 5 or fewer cases in either stratum. In such cases, we still estimated relative risks between other exposure strata and the reference strata if those strata were not sparse. For rare outcomes, we only included one covariate for every 10 observations in the sparsest combination of the exposure and outcome, choosing covariates based on ranked deviance ratios.

6. Pooling parameters

We pooled adjusted estimates from individual cohorts using random effects models, fit using restricted maximum likelihood estimation. The pooling methods are detailed in Benjamin-Chung (2020). All parameters were pooled directly using the cohort-specific estimates of the same parameter, except for population attributable fractions. Pooled PAFs were calculated from random-effects pooled population intervention impacts (PIEs), and pooled outcome prevalence in the population using the following formulas:

$$1078 PAF = \frac{PAR}{Outcome\ prevalence} \times 100 (1)$$

1079
$$PAF 95\%CI = \frac{PAR 95\% CI}{Outcome \ prevalence} \times 100$$
 (2)

For PAFs of exposures on the cumulative incidence of wasting and stunting, the pooled cumulative incidence was substituted for the outcome prevalence in the above equations. We used this method instead of direct pooling of PAFs because, unlike PAFs, PIEs are unbounded with symmetrical confidence intervals.

For figures 3a-c, mean trajectories estimated using cubic splines in individual studies and then curves were pooled using random effects. ⁶ Curves estimated from all anthropometry measurements of children taken from birth to 24 months of age within studies that measured the measure of maternal anthropometry.

7. Sensitivity analyses

We compared estimates pooled using random effects models, which are more conservative in the presence of heterogeneity across studies, with estimates pooled using fixed effects, and we compared adjusted estimates with estimates unadjusted for potential confounders. We estimated associations between growth faltering and mortality at different ages, after dropping the trials measuring children less frequently than quarterly, and using TMLE instead of Cox proportional hazard models, and we plotted Kaplan Meier curves of child mortality, stratified by measures of early growth faltering. We also conducted a sensitivity analysis on methods of pooling splines of child growth trajectories, stratified by maternal anthropometry. We re-estimated the attributable differences of exposures on WLZ and LAZ at 24 months, dropping the PROBIT trial, the only European study. Results from secondary outcomes and sensitivity analyses are viewable online at https://child-growth.github.io/causes.

Data and code availability

The data that support the findings of this study are available from the Bill and Melinda Gates Foundation Knowledge Integration project upon reasonable request. Replication scripts for this analysis are available here: https://github.com/child-growth/ki-longitudinal-growth.

Methods References

1107

1108

- 1. WHO | The WHO Child Growth Standards. WHO http://www.who.int/childgrowth/en/.
- Organization, W. H. & Fund (UNICEF), U. N. C. *Recommendations for data collection, analysis and reporting on anthropometric indicators in children under 5 years old.* (World Health Organization, 2019).
- 1112 3. Benjamin-Chung, J. et. al. (submitted). Early childhood linear growth faltering in low-and middle-income countries. (2020).
- 1114 4. Mertens, A. *et al.* (submitted). Child wasting and concurrent stunting in low- and middle-income countries. (2020).
- 1116 5. Wood, S. N., Pya, N. & Säfken, B. Smoothing Parameter and Model Selection for General Smooth Models. *J. Am. Stat. Assoc.* 111, 1548–1563 (2016).
- 1118 6. Gasparrini, A., Armstrong, B. & Kenward, M. G. Multivariate meta-analysis for non-linear and other multi-1119 parameter associations. *Stat. Med.* **31**, 3821–3839 (2012).
- 1120 7. Luedtke, A. R. & van der Laan, M. J. Super-Learning of an Optimal Dynamic Treatment Rule. *Int. J. Biostat.* **12**, 305–332 (2016).
- 1122 8. Jewell, N. P. Statistics for epidemiology. (Boca Raton: Chapman & Hall/CRC., 2004).
- 1123 9. Greenland, S., Robins, J. M. & Pearl, J. Confounding and Collapsibility in Causal Inference. *Stat. Sci.* **14**, 29–46 (1999).
- 1125 10. VanderWeele, T. J. & Shpitser, I. A new criterion for confounder selection. *Biometrics* 67, 1406–1413 (2011).
- 1126 11. Groenwold, R. H. H., Palmer, T. M. & Tilling, K. To Adjust or Not to Adjust? When a "Confounder" Is Only Measured After Exposure. *Epidemiol. Camb. Mass* 32, 194–201 (2021).
- 1128 12. McNutt, L.-A., Wu, C., Xue, X. & Hafner, J. P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am. J. Epidemiol.* **157**, 940–943 (2003).
- 1130 13. Gruber, S. & Laan, M. van der. Targeted Maximum Likelihood Estimation: A Gentle Introduction. *UC Berkeley Div. Biostat. Work. Pap. Ser.* (2009).
- 14. Laan, M. J. van der & Rose, S. *Targeted Learning: Causal Inference for Observational and Experimental Data*.(Springer-Verlag, 2011).
- 1134 15. VanderWeele, T. J. & Ding, P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann. Intern. Med.* **167**, 268 (2017).
- 1136 16. van der Laan, M., Polley, E. & Hubbard, A. Super Learner. *UC Berkeley Div. Biostat. Work. Pap. Ser.* (2007).
- 1137 17. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *J. R. Stat. Soc. Ser. B Methodol.* **58**, 267–288 (1996).
- 1139 18. Hastie, T. & Tibshirani, R. Generalized Additive Models. Stat. Sci. 1, 297–310 (1986).
- 1140 19. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. *Proc. 22nd ACM SIGKDD Int. Conf. Knowl. Discov. Data Min. KDD 16* 785–794 (2016) doi:10.1145/2939672.2939785.
- 1142 20. Population attributable risk (PAR). in *Encyclopedia of Public Health* (ed. Kirch, W.) 1117–1118 (Springer Netherlands, 2008). doi:10.1007/978-1-4020-5614-7_2685.

<u>Acknowledgments</u>

1144 1145 1146

- 1147 This research was financially supported by a global development grant (OPP1165144)
- 1148 from the Bill & Melinda Gates Foundation to the University of California, Berkeley, CA,
- 1149 USA. We would also like to thank the following collaborators on the included cohorts
- and trials for their contributions to study planning, data collection, and analysis:
- 1151 Muhammad Sharif, Sajjad Kerio, Ms. Urosa, Ms. Alveen, Shahneel Hussain, Vikas

- 1152 Paudel (Mother and Infant Research Activities), Anthony Costello (University College
- 1153 London), Noel Rouamba, Jean-Bosco Ouédraogo, Leah Prince, Stephen A Vosti,
- 1154 Benjamin Torun, Lindsey M Locks, Christine M McDonald, Roland Kupka, Ronald J
- 1155 Bosch, Rodrick Kisenge, Said Aboud, Molin Wang, Azaduzzaman, Abu Ahmed
- 1156 Shamim, Rezaul Haque, Rolf Klemm, Sucheta Mehra, Maithilee Mitra, Kerry Schulze,
- 1157 Sunita Taneja, Brinda Nayyar, Vandana Suri, Poonam Khokhar, Brinda Nayyar,
- 1158 Poonam Khokhar, Jon E Rohde, Tivendra Kumar, Jose Martines, Maharaj K Bhan, and
- all other members of the study staffs and field teams. We would also like to thank all
- 1160 study participants and their families for their important contributions. We are grateful to
- the LCNI5 and iLiNS research teams, participants and people of Lungwena, Namwera,
- 1162 Mangochi and Malindi, our research assistants for their positive attitude, support, and
- 1163 help in all stages of the studies.

Author contributions

- 1166 Conceptualization: A.M., J.B., J.M.C., K.H.B., P.C., B.F.A
- 1167 Funding Acquisition: J.M.C., A.E.H., M.J.V., B.F.A.
- 1168 Data curation: A.M., J.B., J.C., O.S., W.C., A.N., N.N.P., W.J., E.C, E.O.C., S.D., N.H.,
- 1169 I.M., H.L., R.H., V.S., J.H., T.N.
- 1170 Formal analyses: A.M., J.B., J.C., O.S., W.C., A.N., N.N.P., W.J., E.C, E.O.C., S.D.,
- 1171 N.H., I.M., H.L., V.S., B.F.A
- 1172 Methodology: A.M., J.B., J.M.C, J.C., O.S., N.H., I.M., A.E.H., M.J.V., K.H.B., P.C.,
- 1173 B.F.A.

1164

1165

1178

1184

1185

1188

1191

- 1174 Visualization: A.M., J.B., A.N., N.N.P., S.D., A.S., E.C, J.C., R.H., K.H.B., P.C., B.F.A.
- 1175 Writing Original Draft Preparation: A.M., J.B., B.F.A.
- 1176 Writing Review & Editing: A.M., J.B., J.M.C., K.H.B., P.C., B.F.A., ki Child Growth
- 1177 Consortium members

1179 Competing interest declaration

- 1180 Thea Norman is an employee of the Bill & Melinda Gates Foundation (BMGF). Kenneth
- 1181 H Brown and Parul Christian are former employees of BMGF. Jeremy Coyle, Vishak
- 1182 Subramoney, Ryan Hafen, and Jonas Häggström work as research contractors funded
- 1183 by the BMGF.

Additional information

- 1186 Supplementary Information is available for this paper at https://child-
- 1187 growth.github.io/causes.
- 1189 Correspondence and requests for materials should be addressed to Andrew Mertens
- 1190 (amertens@berkeley.edu) and Benjamin F. Arnold (ben.arnold@ucsf.edu).